Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1955 1
1956 1
1957 2
1959 1
1963 1
1964 2
1965 1
1966 1
1968 1
1969 2
1970 1
1971 2
1972 1
1974 2
1975 3
1976 2
1977 2
1978 3
1980 3
1981 3
1982 3
1983 4
1984 5
1985 6
1986 6
1987 6
1988 12
1989 7
1990 17
1991 10
1992 8
1993 13
1994 7
1995 10
1996 13
1997 12
1998 15
1999 8
2000 26
2001 25
2002 40
2003 30
2004 35
2005 40
2006 38
2007 39
2008 40
2009 60
2010 66
2011 76
2012 90
2013 72
2014 74
2015 102
2016 115
2017 100
2018 126
2019 133
2020 141
2021 173
2022 160
2023 180
2024 201
2025 238
2026 74

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,379 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Peng Z, et al. J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3. J Clin Oncol. 2023. PMID: 35921605 Clinical Trial.
Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC. ...Patients with primary treatment-naive or initial recurrent advanced HCC after surgery wer …
Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN …
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Bartlett NL, et al. J Clin Oncol. 2025 Mar 20;43(9):1061-1072. doi: 10.1200/JCO-24-02242. Epub 2025 Jan 7. J Clin Oncol. 2025. PMID: 39772655 Free PMC article. Clinical Trial.
METHODS: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 w …
METHODS: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo …
Practical Management of Lenalidomide-Related Rash.
Tinsley SM, Kurtin SE, Ridgeway JA. Tinsley SM, et al. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S64-9. doi: 10.1016/j.clml.2015.02.008. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26297281 Review.
The toxicity profile for LEN is similar across indications, with the most common adverse events reported in registration trials being hematologic in nature, and Grade 3 hematologic toxicities the most common reasons for treatment interruption or permanent LEN disc …
The toxicity profile for LEN is similar across indications, with the most common adverse events reported in registration trials being …
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
RESULTS: Of 954 patients in the overall population, 168 Japanese patients were assigned to the LEN arm (N = 81) or the SOR arm (N = 87). Median OS was 17.6 months for LEN vs. 17.8 months for SOR (HR 0.90; 95% CI 0.62-1.29). LEN showed statistically significan …
RESULTS: Of 954 patients in the overall population, 168 Japanese patients were assigned to the LEN arm (N = 81) or the SOR arm (N = 8 …
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y. Kudo M, et al. Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344448 Free PMC article.
The relative dose intensity of LEN before the first TACE was important for achieving higher CR rate/ORR by LEN-TACE. ...CONCLUSION: The results of this trial provide encouraging evidence, supporting the efficacy and favorable safety profile of LEN-TACE in pat …
The relative dose intensity of LEN before the first TACE was important for achieving higher CR rate/ORR by LEN-TACE. ...CONCLU …
Applying a non-GMO breeding approach with an identified natural variation to reduce food allergen Len c3 in Lens culinaris seeds.
Song J, Mavraganis I, Shen W, Yang H, Zou J. Song J, et al. Front Plant Sci. 2024 Apr 12;15:1355902. doi: 10.3389/fpls.2024.1355902. eCollection 2024. Front Plant Sci. 2024. PMID: 38742216 Free PMC article.
However, lentil causes food allergy, which has been a significant concern due to increased consumption in parts of the world. Len c3, a non-specific lipid transfer protein (LTP), was identified as one of the allergens in lentil seeds. In this study, we identified an LTP ge …
However, lentil causes food allergy, which has been a significant concern due to increased consumption in parts of the world. Len c3, …
A Randomized Controlled Trial of Tong Len Meditation Practice in Cancer Patients: Evaluation of a Distant Psychological Healing Effect.
Pagliaro G, Pandolfi P, Collina N, Frezza G, Brandes A, Galli M, Avventuroso FM, De Lisio S, Musti MA, Franceschi E, Esposti RD, Lombardo L, Cavallo G, Di Battista M, Rimondini S, Poggi R, Susini C, Renzi R, Marconi L. Pagliaro G, et al. Explore (NY). 2016 Jan-Feb;12(1):42-9. doi: 10.1016/j.explore.2015.10.001. Epub 2015 Oct 26. Explore (NY). 2016. PMID: 26657031 Clinical Trial.
CONTEXT: Tong Len meditation is an important therapeutic tool in the Tibetan medicine, and it can be used for self-healing and/or to heal others. Currently, in the West, there is no scientific study concerning the efficacy of a Tong Len distant healing effect on psy …
CONTEXT: Tong Len meditation is an important therapeutic tool in the Tibetan medicine, and it can be used for self-healing and/or to …
Lenacapavir: a first-in-class capsid inhibitor for HIV treatment and prevention.
McKellar MS. McKellar MS. Curr Opin Infect Dis. 2025 Jun 1;38(3):208-213. doi: 10.1097/QCO.0000000000001113. Epub 2025 Apr 23. Curr Opin Infect Dis. 2025. PMID: 40276818 Review.
RECENT FINDINGS: LEN has been approved in the United States as both oral tablets and injectable solution for treatment in heavily treatment-experienced adults with multidrug-resistant HIV-1. The subcutaneous injections are administered every 26 weeks (6 months). In 2024, …
RECENT FINDINGS: LEN has been approved in the United States as both oral tablets and injectable solution for treatment in heavily tre …
Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma.
Zhao L, Ma H, Jiang Y, Li Y, Guo N, Chen Y, Jiang X, Zhao Y, Yang J, Liu Y, Wen K, Wang L, Jian L, Fan X. Zhao L, et al. Phytomedicine. 2024 Dec;135:156002. doi: 10.1016/j.phymed.2024.156002. Epub 2024 Sep 1. Phytomedicine. 2024. PMID: 39326134
RESULTS: Len resistance in HCC is related to the increased m6A level and the high expression of METTL3. ...Len-resistant CDX and PDX models revealed that Res can reverse the resistant phenotype, with the tumor inhibition rates of 77.46 % and 62.1 %, respectively, wh …
RESULTS: Len resistance in HCC is related to the increased m6A level and the high expression of METTL3. ...Len-resistant CDX a …
Expression of Leptospira membrane proteins Signal Peptidase (SP) and Leptospira Endostatin like A (Len A) in BL-21(DE3) is toxic to the host cells.
Satheeshkumar PK, Anu PV, Junaida MI, Madanan MG, Jebasingh T, Nair AJ, Nair GA, Nair GPM, Sudhakaran PR. Satheeshkumar PK, et al. J Genet Eng Biotechnol. 2018 Dec;16(2):393-398. doi: 10.1016/j.jgeb.2018.01.004. Epub 2018 Feb 2. J Genet Eng Biotechnol. 2018. PMID: 30733752 Free PMC article.
In the present study, two transmembrane proteins of the pathogen Leptospira interrogans, namely Signal peptidase (SP), and Leptospira Endostatin like A (Len-A) were taken along with a cytosolic protein Hydrolase (HYD) to assess the differences in transformation efficiency, …
In the present study, two transmembrane proteins of the pathogen Leptospira interrogans, namely Signal peptidase (SP), and Leptospira Endost …
2,379 results